Repligen CEO exercises, sells 5,426 shares
Repligen’s CEO and director exercised options for 5,426 shares and sold the same amount under a pre-arranged Rule 10b5-1 trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
REPLIGEN CORP (RGEN) reported that its chief executive officer and director, Loeillot Olivier, exercised employee stock options and sold the resulting shares. On September 21, 2026, he exercised options to acquire 5,426 shares of Common Stock at an exercise price of $141.79 per share, then sold 5,426 shares at $180.00 per share. The filing states that these sales were made under a Rule 10b5-1 trading plan adopted on August 19, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 5,426 shares ($207K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Loeillot Olivier
Role
Chief Executive Officer
Sold
5,426 shs ($977K)
Approx. gross sale proceeds
$977K
Approx. exercise cost
$769K
Approx. pre-tax spread
$207K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 5,426 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 5,426 | $141.79 | $769K |
| Sale | Common Stock F1 | 5,426 | $180.00 | $977K |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,426 options (Direct);
Common Stock — 48,369 shares (Direct)
Footnotes (1)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
Key Figures
Shares exercised: 5,426 shares
Option exercise price: $141.79 per share
Shares sold: 5,426 shares
+4 more
7 metrics
Shares exercised
5,426 shares
Options exercised into Common Stock on September 21, 2026
Option exercise price
$141.79 per share
Exercise price for 5,426 shares of Common Stock
Shares sold
5,426 shares
Common Stock sold on September 21, 2026
Sale price
$180.00 per share
Per-share sale price for 5,426 shares of Common Stock
Rule 10b5-1 plan adoption date
August 19, 2025
Date the CEO adopted the trading plan used for these sales
Derivative transaction count
1 transaction
One reported option exercise involving 5,426 shares
Net shares sold
5,426 shares
Netted from one exercise and one sale of the same number of shares
Key Terms
Rule 10b5-1 trading plan, stock option, derivative security
3 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option financial
"Stock Option (Right to Buy) is listed as a derivative security"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"Stock Option (Right to Buy) is reported as a derivative security related to Common Stock"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did RGEN’s CEO report on September 21, 2026?
Loeillot Olivier reported exercising options to acquire 5,426 shares of Repligen Common Stock at $141.79 per share and selling 5,426 shares at $180.00 per share on September 21, 2026, in an exercise-and-sell transaction.
What was the exercise price of the options used by Repligen’s CEO?
The options exercised by Loeillot Olivier had an exercise price of $141.79 per share, covering 5,426 shares of Repligen Common Stock, and were exercised on September 21, 2026.
Was the Repligen (RGEN) CEO’s stock sale under a Rule 10b5-1 trading plan?
Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Loeillot Olivier on August 19, 2025, indicating they followed a pre-arranged schedule.
What is the role of the insider involved in this Repligen (RGEN) Form 4?
The reporting person, Loeillot Olivier, is identified as both a director and the Chief Executive Officer of Repligen Corp in the Form 4 ownership report.
Did the Repligen CEO’s Form 4 involve derivative securities?
Yes. The Form 4 shows the exercise of a stock option, a derivative security, to acquire 5,426 shares of Repligen Common Stock at an exercise price of $141.79 per share before selling the underlying shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
